US 12,233,086 B2
Biomarkers for neurogenerative disease
Arasteh Azhir, Los Altos, NY (US); Michael S. McGrath, Meadow Vista, CA (US); and Bruce D. Forrest, Nyack, NY (US)
Assigned to NEUVIVO, INC., Palo Alto, CA (US); and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by Neuvivo, Inc., Palo Alto, CA (US); and The Regents of the University of California, Oakland, CA (US)
Filed on May 17, 2023, as Appl. No. 18/319,355.
Claims priority of provisional application 63/484,678, filed on Feb. 13, 2023.
Claims priority of provisional application 63/410,724, filed on Sep. 28, 2022.
Claims priority of provisional application 63/392,237, filed on Jul. 26, 2022.
Claims priority of provisional application 63/343,568, filed on May 19, 2022.
Prior Publication US 2023/0390331 A1, Dec. 7, 2023
Int. Cl. A61K 33/20 (2006.01); A61P 25/28 (2006.01); G01N 33/68 (2006.01)
CPC A61K 33/20 (2013.01) [A61P 25/28 (2018.01); G01N 33/6863 (2013.01); G01N 33/6896 (2013.01); G01N 2333/495 (2013.01); G01N 2800/2835 (2013.01); G01N 2800/52 (2013.01)] 18 Claims
 
1. A method of treating a neurodegenerative disease in a subject in need thereof, the method comprising:
a) obtaining a first level of a biomarker in the subject;
b) subsequent to obtaining the first level of the biomarker in the subject, administering to the subject a therapeutic regimen of sodium chlorite;
c) subsequent to the administering to the subject the therapeutic regimen of sodium chlorite, obtaining a second level of the biomarker in the subject;
d) subsequent to obtaining the second level of the biomarker in the subject, comparing the first level of the biomarker in the subject to the second level of the biomarker in the subject to identify a change from the first level of the biomarker in the subject to the second level of the biomarker in the subject; and
e) based at least in part on the change from the first level of the biomarker in the subject to the second level of the biomarker in the subject, recommending that the subject continue the therapeutic regimen of sodium chlorite, wherein the change from the first level of the biomarker in the subject to the second level of the biomarker in the subject is an increase,
wherein the biomarker is TGFB1.